Results 121 to 130 of about 6,043 (171)
Some of the next articles are maybe not open access.
New cardiotonic agents: A search for digitalis substitute
Life Sciences, 1978Adawia A Alousi
exaly +3 more sources
Cardiotonic agents and the sodium transient
Trends in Pharmacological Sciences, 1981Abstract The authors discuss the possible link between membrane excitation and the calcium transient in cardiac muscle.
Tai Akera, Theodore M. Brody
openaire +1 more source
Synthesis of Amrinone, A Cardiotonic Agent
Journal of the Chinese Chemical Society, 1988AbstractA new synthesis of amrinone, 1, from 5‐(4‐pyridinyl) −2(1H)‐pyridone, 5, is reported. Nitration at C‐3 of the pyridone ring of 5 followed by reduction afforded amrinone. Another synthetic route was also carried out by bromination at C‐3 of the pyridone ring of 5 followed by substitution with sodium azide to give the corresponding azide ...
Min‐Jen Shiao +2 more
openaire +1 more source
Synthesis of Milrinone, a Cardiotonic Agent
HETEROCYCLES, 1990A new synthesis of milrinone from 6-methyl-5-(4-pyridinyl)-2(1H)-pyridone is reported. A convenient synthesis of 3,4'-bipyridines is achieved. They can be converted into pyridone by hydrogenolysis and hydrolysis, respectively.
Min-Jen Shiao +2 more
openaire +1 more source
Cardiovascular Pharmacology of the Vasodilator-Cardiotonic Agent, 349U85
Journal of Cardiovascular Pharmacology, 1992349U85 is a chemically novel, nonglycoside, noncatecholamine cardiotonic-vasodilator agent with a unique cardiovascular profile in vitro and in vivo. 349U85 and milrinone, 10(-6) to 3 x 10(-5) M each, produce concentration-dependent increases in tension development of 33-60% and 37-60%, respectively, with corresponding 5-18% and 17-55% increases in ...
R P, Steffen, W B, Wastila
openaire +2 more sources
Cardiotonic agents in the management of chronic cardiac failure
American Heart Journal, 1982Heart failure is a syndrome with distinct clinical signs and symptoms. The severity of cardiac failure and a deterioration in functional capacity can be determined by a progressive exercise test and by the noninvasive determination of maximum oxygen uptake.
K T, Weber, V, Andrews, J S, Janicki
openaire +2 more sources
European Journal of Pharmacology, 1987
The effect on the contractile protein system of MCI-154, a novel and potent cardiotonic agent, was examined by using thin bundles of chemically skinned fibers from the guinea-pig papillary muscles. MCI-154 increased the Ca2+ sensitivity of the contractile protein system of the cardiac skinned fibers.
Y, Kitada +3 more
openaire +2 more sources
The effect on the contractile protein system of MCI-154, a novel and potent cardiotonic agent, was examined by using thin bundles of chemically skinned fibers from the guinea-pig papillary muscles. MCI-154 increased the Ca2+ sensitivity of the contractile protein system of the cardiac skinned fibers.
Y, Kitada +3 more
openaire +2 more sources
Scaffold evaluation of liguzinediol analogs as novel cardiotonic agents
Die Pharmazie, 2013Liguzinediol (LZDO) could mediate the positive inotropic effects through sarcoplasmic reticulum Ca2+ ATPase-dependent mechanism without the risk of arrhythmia. However, the pharmacophore of LZDO contributed to the activities was not clear. The aim of this work was to explore the relationship between positive inotropic effect and scaffold of LZDO as ...
Liu, Z. +8 more
openaire +2 more sources
Cardiovascular Properties of a New Cardiotonic Agent, MDL 19205
Journal of Cardiovascular Pharmacology, 1984The cardiovascular properties of a new cardiotonic agent, MDL 19205, were investigated in anesthetized and conscious dogs and in a dog heart-lung preparation. MDL 19205 (0.1-1 mg/kg), administered to anesthetized dogs by intravenous injection, produced a dose-related increase in cardiac contractile force lasting up to 1 h. It also produced a relatively
R C, Dage +3 more
openaire +2 more sources
Cardiotonic Agent SCH00013 Prolongs Survival of Cardiomyopathic Hamsters
Journal of Cardiovascular Pharmacology, 2003The authors examined the effects of long-term treatment with SCH00013, a novel cardiotonic agent with calcium-sensitizing action, on survival of hereditary cardiomyopathic BIO 14.6 hamsters. Sixty-nine male hamsters at 223 days of age were divided into untreated, SCH00013-low (approximately 1 mg/kg/d), and SCH00013-high (approximately 10 mg/kg/d ...
Tadahito, Narita +4 more
openaire +2 more sources